Joseph H. Antin, MD, Dana-Farber Cancer Institute

home / authors / joseph-h-antin-md-dana-farber-cancer-institute

Articles

Treating Chronic Graft-vs-Host Disease

Treating Chronic Graft-vs-Host Disease

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Graft-vs-Host Disease Prophylaxis Clinical Trials

Graft-vs-Host Disease Prophylaxis Clinical Trials

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Special Transplant Situations

Special Transplant Situations

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Risk Factors for Graft-vs-Host Disease

Risk Factors for Graft-vs-Host Disease

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Overview of Graft-Vs-Host Disease

Overview of Graft-Vs-Host Disease

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Members of the Transplant Team

Members of the Transplant Team

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Timing of Referral for Transplant

Timing of Referral for Transplant

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute;Joseph H. Antin, MD, Dana-Farber Cancer Institute;Yi-Bin A. Chen, MD, Massachusetts General Hospital;Zachariah M. DeFilipp, MD, Massachusetts General Hospital
June 19th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data